Brokerages Set Omnicell, Inc. (NASDAQ:OMCL) Price Target at $47.83

Omnicell, Inc. (NASDAQ:OMCL) has earned an average recommendation of “Hold” from the eight research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $47.8333.

Several brokerages have commented on OMCL. Benchmark boosted their price target on shares of Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Omnicell in a research report on Wednesday, October 8th. Wells Fargo & Company increased their price target on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. KeyCorp raised Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective on the stock in a research note on Wednesday. Finally, Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th.

Key Headlines Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Neutral Sentiment: Zacks keeps a “Hold” rating on OMCL and notes the consensus full‑year estimate still near $1.09, signaling neither a buy nor sell posture from that shop. Zacks Research note
• Negative Sentiment: Zacks cut FY2026 and FY2027 EPS forecasts (FY2026: from $1.03 to $0.93; FY2027: from $1.10 to $1.00) — a downward reset to multi‑year guidance that could pressure forward valuation multiples and near‑term investor confidence. Zacks Research note
• Negative Sentiment: Multiple quarterly EPS estimates were trimmed across 2025–2027 (examples: Q1 2026 cut to $0.09 from $0.11; Q2 2026 to $0.20 from $0.22; Q3 2026 to $0.29 from $0.32; Q4 2026 to $0.34 from $0.38; and several 2027 quarters reduced). These repeated downgrades suggest Zacks expects slower near‑term operating leverage or revenue pressure. Zacks Research note
• Negative Sentiment: Zacks also trimmed FY2025 and Q4 2025 EPS estimates, indicating the cuts are not limited to forward years but reflect near-term softness as well. That broad scope of reductions increases the chance of lower short‑term earnings surprises. Zacks Research note

Omnicell Stock Performance

NASDAQ:OMCL opened at $50.74 on Thursday. Omnicell has a 1 year low of $22.66 and a 1 year high of $51.30. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.44 and a quick ratio of 1.21. The company has a market capitalization of $2.28 billion, a P/E ratio of 118.00, a P/E/G ratio of 5.23 and a beta of 0.77. The business has a fifty day simple moving average of $41.06 and a two-hundred day simple moving average of $34.28.

Hedge Funds Weigh In On Omnicell

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC grew its position in Omnicell by 219.4% in the 4th quarter. SG Americas Securities LLC now owns 20,547 shares of the company’s stock valued at $931,000 after acquiring an additional 14,114 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Omnicell by 83.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock valued at $11,698,000 after purchasing an additional 117,556 shares during the period. Diversified Trust Co. grew its holdings in shares of Omnicell by 7.5% in the fourth quarter. Diversified Trust Co. now owns 7,965 shares of the company’s stock worth $361,000 after purchasing an additional 555 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new position in Omnicell in the 3rd quarter worth about $224,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Omnicell during the 3rd quarter valued at about $1,924,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.